In our Department of Urology, from June ‘88 to February ‘92, 135 patients, with superficial transitional cell papillary carcinoma of the bladder, T1G2, were treated with intravesical antiblastic instillations, after therapeutic transurethral resection. 45 patients (33%) were treated with Mitomycin C; 40 patients (30%) were treated with Doxorubicin; 50 patients (37%) were treated with B.C.G. Pasteur. In the Mitomycin Ck group (follow-up 6.’88 ÷ 2.’92), only 20 patients out of 45 (i.e. 44%) were free of tumor at 30.5 months. Of the 16 patients with unifocal carcinoma, 12 patients (i.e. 75%) had no recurrences at 31.2 months, while of the 29 patients with multifocal carcinoma only 8 patients (i.e. 25%) were free of tumor at 29.1 months. In the Doxorubicin group, (follow-up 10.’89 ÷ 2.’92) 33 patients out of 40 (i.e. 82%) were free of tumor at 16.5 months. Of the 15 patients with unifocal carcinoma, 13 (i.e. 86%) had no recurrences at 17 months, while of the 25 patients with multifocal carcinoma 20 (i.e. 80%) were free of tumor at 18.4 months. As to the B.C.G. group (follow-up 11.’89 ÷ 2.’92), 35 patients out of 50 (i.e. 70%) were free of tumor at 13 months. Of the 6 patients with unifocal carcinoma 5 (i.e. 83%) had no recurrences at 7 months, while of the 44 patients with multifocal carcinoma 30 (i.e. 68%) were free of tumor at 13 months. In conclusion, the above reported data show that the best results were obtained in patients treated with Doxorubicin instillations, without significant difference between the results of unifocal and of multifocal carcinoma. Intermediate results were obtained in patients treated with B.C.G., with a moderate but significant difference between unifocal and multifocal carcinoma. The patients treated with Mitomycin C yielded the worst results, and the difference between unifocal and multifocal carcinoma was substantial
